In-Depth Research on Global Factor IX Deficiency Treatment Market 2017-2021

Report : Global Factor IX Deficiency Treatment Market 2017-2021 is a new market research publication announced by Reportstack. 

Report Outline: The global factor IX deficiency treatment market is characterized by the presence of various therapeutic products provided by some of the top vendors such as Shire, CSL Behring, Novo Nordisk, Biogen, and Pfizer. The adoption rate of therapeutics has undergone a paradigm shift toward the introduction of gene therapy, which will lead to the development of new products. However, the low penetration rate of recombinant therapy in developing countries is the current challenge in the market. This low penetration rate in developing countries is due to the higher cost of recombinant drugs, limited disease knowledge, and a shortage of treatment supplies. Nevertheless, the market has observed a positive side of individuals adopting recombinant drugs is expected to improve the diagnosis and treatment rates for hemophilia B in the medium- to long-term.

For detailed report with TOC, please click here ​Global Factor IX Deficiency Treatment Market 2017-2021

Market Growth: The global factor IX deficiency treatment market to grow at a CAGR of 5.12% during the period 2017-2021.

Key vendors • Biogen
• CSL Behring
• Novo Nordisk
• Pfizer
• Shire

Regions Covered: 

• Americas
• APAC
• EMEA

Companies Mentioned

Biogen, CSL Behring, Novo Nordisk, Pfizer, and Shire.

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

Reportstack Market Research

###